A Phase 1 Study of ARV-393 for People With Non-Hodgkin's Lymphoma

Full Title

A Phase 1 First in Human Study of ARV-393 in Adult Participants with Advanced Non-Hodgkin’s Lymphoma

Purpose

Researchers want to find the best dose of ARV-393 to use in people with non-Hodgkin lymphoma. The people in this study have NHL that keeps growing or came back after treatment.

ARV-393 targets and breaks down a protein called BCL6. This protein is found in cancer cells and plays a role in their growth and survival. By breaking down BCL6, ARV-393 may help slow or stop the growth of your cancer. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have NHL that keeps growing or came back after prior treatment.
• Have recovered from the serious side effects of previous therapies before taking ARV-393.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information and to see if you can join this study, please call Dr. Andrew Zelenetz’s office at 646-608-3728.